Antonio Pinto
YOU?
Author Swipe
View article: Health-Related Quality of Life and Symptom Burden in Patients with Diffuse Large B-Cell Lymphoma Before Treatment with Tafasitamab and Lenalidomide: An Ad Hoc Analysis of Italian Real-World Data from the PRO-MIND Study
Health-Related Quality of Life and Symptom Burden in Patients with Diffuse Large B-Cell Lymphoma Before Treatment with Tafasitamab and Lenalidomide: An Ad Hoc Analysis of Italian Real-World Data from the PRO-MIND Study Open
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) exhibits substantial clinical heterogeneity and poor prognosis in relapsed/refractory (R/R) settings. PRO-MIND is a prospective, multicenter real-world study evaluating tafasitam…
View article: Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis
Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis Open
Background: Despite recent advances, R/R LBCL remains clinically challenging with poor outcomes and a critical need for effective and durable treatment options, particularly for patients with high-risk characteristics. In this open-label, …
View article: Final efficacy results of the real-life ambispective urban study on frontline obinutuzumab-based immunochemotherapy for advanced follicular lymphoma
Final efficacy results of the real-life ambispective urban study on frontline obinutuzumab-based immunochemotherapy for advanced follicular lymphoma Open
Background: The GALLIUM trial established obinutuzumab-based immunochemotherapy as a new standard of care in first-line treatment for patients with advanced follicular lymphoma (FL), demonstrating a superior progression-free survival (PFS)…
View article: Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial
Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial Open
Introduction Registry data, including European Society for Blood and Marrow Transplantation (EBMT) data (Pettengell, BMT 2021), show that Autologous Stem Cell Transplant (ASCT) is commonly used as consolidation in relapsed/refractory (R/R)…
View article: Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma
Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma Open
Background: Follicular lymphoma (FL) has a heterogeneous clinical course, and despite advances in therapy, a significant proportion of patients experiences relapse. Existing prognostic models do not fully capture the biological heterogenei…
View article: Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts
Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts Open
Aggressive large B‐cell lymphomas (LBCL) include a range of disease types characterized by heterogenous histopathologic, molecular, and genetic features. In this review, we summarize the main standardized disease assessments, treatments an…
View article: Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial Open
PURPOSE An unmet need remains for more effective therapies for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), especially high-grade B-cell lymphoma (HGBCL). We present the primary analysis of a phase Ib/II study (ClinicalTrials.go…
View article: Impact of Manchester Triage on the Referral Pathway of Febrile Neutropenia Patients in the Emergency Department – A Single-Center Experience
Impact of Manchester Triage on the Referral Pathway of Febrile Neutropenia Patients in the Emergency Department – A Single-Center Experience Open
Purpose:Febrile neutropenia is a frequent complication of oncological treatment. Empirical antibiotic therapy should be started within the first hour after admission. Delays in its administration are associated with prolonged hospital stay…
View article: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma Open
In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492 ), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free survival (PFS) benefit versus rituxima…
View article: Instruments to Assess Bidirectional Intimate Partner Violence: A Systematic Review
Instruments to Assess Bidirectional Intimate Partner Violence: A Systematic Review Open
Intimate partner violence (IPV) is a significant public health issue that affects individuals, families, and society in profound ways. Over the years, research has often shown that such IPV is predominantly one-sided, with men as perpetrat…
View article: Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study Open
Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami)…
View article: Diffuse vasculopathy in a patient with Marfan syndrome
Diffuse vasculopathy in a patient with Marfan syndrome Open
Marfan syndrome (MFS) is a hereditary connective tissue disorder, primarily affecting the cardiovascular, skeletal, and ocular systems. Cardiovascular complications, particularly aortic aneurysm and dissection, are the leading causes of mo…
View article: The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study
The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study Open
Patients with solid tumors and a higher body mass index (BMI) experience improved survival after receiving anti-PD1 antibodies. The predictive role of BMI in Hodgkin Lymphoma (HL), the most sensitive malignancy to PD1-blockade, remains unc…
View article: Optimization and image quality in CT studies: application of DRLs based on clinical indication
Optimization and image quality in CT studies: application of DRLs based on clinical indication Open
The use of ionizing radiation in computed tomography (CT) has significantly enhanced diagnostic accuracy and clinical decision-making. However, optimizing CT protocols is crucial to balance the diagnostic benefits with potential radiation …
View article: Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the <scp>FOLL12</scp> Trial
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the <span>FOLL12</span> Trial Open
Discordant results have been generated regarding the prognostic role of Total Metabolic Tumor Volume (TMTV) in Follicular Lymphoma (FL). The use of prospective data and the adoption of the newly defined standardized SUV4 method for calcula…
View article: A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA Open
This study analyzed the genetics of classic Hodgkin lymphoma (cHL) by using circulating tumor DNA (ctDNA). Two genetic subtypes were identified, differing in genetic instability mechanisms: one subtype (64% of cases) showed a higher mutati…
View article: A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy
A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy Open
In the Italian setting, mosunetuzumab is a cost-effective treatment option compared to tisagenlecleucel for adult patients with R/R 3L+ FL, presenting favourable outcomes from the perspective of the NHS. Future research and data collection…
View article: Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi Open
We analyzed metabolic response using interim positron emission tomography scan (iPET) in a subset of patients with follicular lymphoma (FL) enrolled in the randomized FOLL12 trial. Patients with grade 1-3a FL with an iPET performed between…
View article: Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm
Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm Open
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens. These molecular markers play a crucial role in diagnosing disease…
View article: A população negra e o acesso à educação nas prisões brasileiras
A população negra e o acesso à educação nas prisões brasileiras Open
Over the years, security policies in Brazil have been incarcerating more Black people, making prisons a place for an increasingly homogeneous population profile. In addition to the conditions that lead Black and Brown people to be imprison…
View article: Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study
Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study Open
Background: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are the standard of care for hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in combination with endocrine therapy. Ho…
View article: Predictive Factors of Antibody–Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review
Predictive Factors of Antibody–Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review Open
Antibody–drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic breast cancer, offering targeted delivery of cytotoxic agents with improved efficacy and tolerability compared to conventional chemotherapy. This na…
View article: Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study
Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study Open
Background Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an easily applicable risk model that can identify patients who will benefit from receiving primary…
View article: Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial
Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial Open
A significant unmet need remains for patients with Hodgkin lymphoma (HL) who fail to respond to first‐line treatment or experience an early relapse. Tinostamustine, a novel alkylating deacetylase inhibitor, inhibits tumor cell growth and s…
View article: Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study
Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study Open
Introduction: Covalent Bruton tyrosine kinase inhibitors (BTKi) have demonstrated monotherapy activity in relapsed/refractory follicular lymphoma (FL), although response rates and progression free survival (PFS) have been limited. Nemtabru…